LOGO
LOGO

Phio Pharma Gets Safety Clearance To Proceed With Dose Escalation In Skin Cancer Study

By RTTNews Staff Writer   ✉  | Published:  | Google News Follow Us  | Join Us
rttnewslogo20mar2024

Phio Pharmaceuticals Corp. (PHIO) has been given the go-ahead by the Safety Monitoring Committee to proceed with dose escalation in its phase Ib clinical trial of PH-762.PH-762, the company's lead drug candidate works by silencing the PD-1 gene implicated in various forms of skin cancer.The phase Ib clinical trial is a multi-center, dose-escalating trial designed to evaluate the safety and tolerab...

Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe Now
Already subscribed? Sign in

For comments and feedback contact: editorial@rttnews.com

Global Economics Weekly Update -May 18 – May 22, 2026

May 22, 2026 14:46 ET
Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.

Latest Updates on COVID-19